Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Five-Year Outcomes With Pembrolizumab Versus Chemotherapy as First-Line Therapy in Patients With Non-Small-Cell Lung Cancer and Programmed Death Ligand-1 Tumor Proportion Score ≥ 1% in the KEYNOTE-042 StudyJ. Clin. Oncol 2022 Oct 28;[EPub Ahead of Print], G de Castro, I Kudaba, YL Wu, G Lopes, DM Kowalski, HZ Turna, C Caglevic, L Zhang, B Karaszewska, KK Laktionov, V Srimuninnimit, I Bondarenko, K Kubota, R Mukherjee, J Lin, F Souza, TSK Mok, BC Cho
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.